

Todos Medical Ltd.

11:30 30 Sep 2020

Todos strikes branding and distribution deal with Melbourne Biotech for RT-PCR machines in US

Todos Medical Ltd (OTCQB:TOMDF) revealed on Wednesday that it has struck an exclusive branding and distribution agreement with Australia-based Melbourne Biotech, a FDA-registered manufacturer, to supply high complexity CLIA labs in the US with 96 and 384 well Real Time Polymerase Chain Reaction (RT-PCR) machines.

The Melbourne RT-PCR machines come with four, five or six channels to be able to identify multiple genes in the same well, said the company.

Todos said it aims to focus the initial deployment of these RT-PCR machines towards its ongoing mobile CLIA lab project that it expects will reach the commercialization stage early in the fourth quarter of 2020.

READ: Todos Medical enters into COVID-19 PCR testing and equipment financing partnership with AID Genomics for US market

"Securing exclusive branding and distribution rights to a high quality RT-PCR machine such as Melbourne for the US market has been a top priority given that we have seen extensive delays in US delivery of other RT-PCR machines since the beginning of the COVID-19 pandemic," Todos Medical CEO Gerald E Commissiong said in a statement.

"We will now be able to source between 100 and 200 Todos branded RT-PCR machines from Melbourne Biotech monthly, which will allow us to scale our ongoing mobile high-complexity CLIA lab collaboration to manufacture up to 100 mobile labs per month. This will facilitate the running of high-throughput PCR testing, around which we will be deploying rapid antigen and rapid antibody testing."

The Todos Medical boss noted that as decision makers begin to realize the "importance" of an "integrated screening and diagnostic confirmation approach" to address the coronavirus (COVID-19) crisis, Todos is well positioned to provide the solutions necessary to allow communities to open safely and stay open.

"We believe mobiles will further add communities' abilities to create the 'bubbles' needed to keep people safe, whether it's on a college campus, on a military base, or whether it is for a sporting event," added Commissiong.


Meanwhile, Shah Awang, Medical Director of Melbourne Biotech, said that when the company was looking for the "appropriate partner" in the US, they sought a company that had a clear vision and approach to addressing the upcoming requirements of COVID testing for the local population.

"We believe the Todos strategy of providing mobile laboratory testing and direct sales of equipment and tests to laboratories is in direct alignment of our goals to assist the population to combat this pandemic," added Dr Awang.

Price: 0.063

Market Cap: \$12.72 m

1 Year Share Price Graph



Share Information

Code: TOMDF

Listing: OTCQB

52 week High Low
0.1815 0.0111

Sector: Medical technology & services

Website: todosmedical.com

Company Synopsis:

Todos Medical Ltd. (OTCQB: TOMDF) an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic ("IVD") company developing a series of blood tests for the early detection of a variety of cancers. Our new cancer tests will add a layer to currently available cancer screening and diagnostics. Our goal is to help save lives through early detection while being minimally invasive to the patient.

action@proactiveinvestors.com

Headquartered in Rehovot, Israel, Todos develops diagnostic solutions to screen for a variety of cancers and neurodegenerative disorders. The company is also active in the COVID-19 PCR testing space.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).